What is the difference between Breztri vs Trelegy?

Trelegy and Breztri are both triple-combination inhalers, but they're approved for different uses. Trelegy can be used for both COPD and asthma in adults, while Breztri is only for COPD.

Trelegy Ellipta, made by GSK, got FDA approval in 2017. Trelegy is a dry powder inhaler that combines three medicines: an inhaled steroid (fluticasone), a long-acting muscarinic antagonist (LAMA) (umeclidinium), and a long-acting beta-agonist (LABA) (vilanterol). Doctors might prescribe Trelegy for people who are already using Breo Ellipta (which has two of these medicines) but need extra help with their breathing. It's important to note that Trelegy isn't for quick relief of sudden breathing problems.

Breztri Aerosphere, produced by AstraZeneca, was approved more recently in 2020. Like Trelegy, it also combines three types of medicine but uses different drugs with similar ways of working to those in Trelegy: budesonide (a corticosteroid), glycopyrrolate (a LAMA), and formoterol (a LABA). Breztri is a metered dose inhaler, which means it sprays out a mist. People use it twice a day, taking two puffs each time. Breztri is only for COPD and isn't approved for asthma or quick relief of breathing difficulties.

Both of these inhalers are meant for long-term, regular use to help manage breathing problems in adults with COPD. They're not meant for children or emergency situations when someone is having trouble breathing.